Bioventus BVS Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total Net Sales by Business | ||||||
| International Segment | $68.28M+5.6% | $65.99M-0.7% | $66.01M+2.1% | $66.73M+5.6% | $64.65M+3.3% | |
| U.S. Segment | $508.02M+1.0% | $502.1M-0.9% | $497.82M+1.5% | $497.41M+5.0% | $503.05M+9.3% | |
| Adjusted Earnings Before Interest, Taxes, Depreciation, Amortization And Other Non-Operating Items by Business | ||||||
| International Segment | $15.93M+24.9% | $15.31M+13.7% | $14.44M+27.2% | $15.17M+48.1% | $12.75M+17.8% | |
| U.S. Segment | $105.05M+13.3% | $100.97M+5.8% | $93.38M+2.3% | $89.61M-1.1% | $92.72M+10.8% | |
| Adjusted other segment expense by Business | ||||||
| International Segment | $66K+110% | $188K+146% | -$115K+39.2% | -$637K-377% | -$691K-2,659% | |
| U.S. Segment | $395K-49.0% | $1.55M+539% | $1.42M+361% | $1.1M+268% | $774K+183% | |
| Adjusted cost of sales by Business | ||||||
| International Segment | $26.03M+8.9% | $24.86M+2.8% | $24.34M+1.1% | $23.96M-4.2% | $23.9M-3.5% | |
| U.S. Segment | $113.33M-4.6% | $113.82M-4.3% | $115.96M+2.9% | $117.13M+6.1% | $118.77M+9.9% | |
| Adjusted research and development expense by Business | ||||||
| International Segment | $38K+11.8% | $41K0.0% | $35K-9.7% | $44K+31.3% | $34K+2.3% | |
| U.S. Segment | $10.73M-17.7% | $11.27M-14.3% | $11.58M-10.1% | $12.44M+2.2% | $13.04M+13.2% | |
| Adjusted general and administrative expense by Business | ||||||
| International Segment | $9.94M-28.2% | $9.33M-37.6% | $11.57M-13.1% | $12.82M+0.5% | $13.84M+12.7% | |
| U.S. Segment | $98.42M+0.9% | $97.5M-0.1% | $96.83M+2.1% | $97.75M+7.4% | $97.56M+11.0% | |
| Adjusted selling expense by Business | ||||||
| International Segment | $12.81M+10.6% | $12.69M+12.9% | $12.22M+7.7% | $12.1M+5.2% | $11.58M-1.8% | |
| U.S. Segment | $155.6M+0.1% | $152.08M-3.6% | $153.37M+2.6% | $154.13M+5.7% | $155.52M+9.4% | |
| Adjusted marketing expense by Business | ||||||
| International Segment | $3.47M+7.3% | $3.59M+19.4% | $3.52M+21.9% | $3.27M+14.4% | $3.23M+22.8% | |
| U.S. Segment | $24.5M-0.7% | $24.92M+2.8% | $25.28M+4.7% | $25.27M+4.7% | $24.66M+2.0% | |
| Total Net Sales by Product | ||||||
| Pain Treatments | $283.57M+7.6% | $279.06M+6.8% | $268.62M+6.9% | $264.57M+9.4% | $263.52M+14.0% | |
| Restorative Therapies | $86.29M-23.0% | $85.37M-30.4% | $93.37M-23.9% | $102M-15.7% | $111.99M-9.8% | |
| Surgical Solutions | $206.45M+7.4% | $203.65M+7.6% | $201.84M+11.4% | $197.57M+13.5% | $192.2M+14.8% | |
| Total Net Sales by Geography | ||||||
| International | $68.28M+5.6% | $65.99M-0.7% | $66.01M+2.1% | $66.73M+5.6% | $64.65M+3.3% | |
| U.S. | $508.02M+1.0% | $502.1M-0.9% | $497.82M+1.5% | $497.41M+5.0% | $503.05M+9.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Bioventus break its business down?
- Bioventus (BVS) reports total net sales by business across 2 parts — International Segment and U.S. Segment. Each is extracted from the segment footnotes and tracked over time.
- Where does Bioventus's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Bioventus's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
